Cell Source, Inc. (CLCS)
- Previous Close
0.0002 - Open
0.0002 - Bid --
- Ask --
- Day's Range
0.0002 - 0.0002 - 52 Week Range
0.0002 - 0.7400 - Volume
1,000 - Avg. Volume
7,878 - Market Cap (intraday)
7,709 - Beta (5Y Monthly) -150.90
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was incorporated in 2012 and is headquartered in New York, New York.
cell-source.comRelated News
Performance Overview: CLCS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLCS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLCS
Valuation Measures
Market Cap
7.71k
Enterprise Value
9.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-900.94%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-6.8M
Diluted EPS (ttm)
-0.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
2.58k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.08M
Company Insights: CLCS
CLCS does not have Company Insights